Akeso Biopharma, Inc., a leading biopharmaceutical company headquartered in China, is at the forefront of innovative drug development. Founded in 2012, Akeso has rapidly established itself within the biotechnology industry, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in major operational regions across Asia and beyond, Akeso is renowned for its unique portfolio of core products, including innovative therapies for oncology and autoimmune diseases. The company has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. Akeso's commitment to advancing healthcare through cutting-edge biopharmaceutical solutions underscores its reputation as a key player in the global biopharma landscape.
How does Akeso Biopharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Akeso Biopharma, Inc.'s score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Akeso Biopharma, Inc., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Akeso Biopharma may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific emissions data or commitments, it is unclear how Akeso Biopharma aligns with these industry trends. As the company evolves, it may consider adopting industry-standard climate initiatives to enhance its environmental responsibility and transparency.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akeso Biopharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.